What empiric antibiotic should be prescribed for a patient with acute febrile illness presenting with abdominal pain?

Empiric Antibiotic Selection for Acute Febrile Illness with Abdominal Pain

For a patient presenting with acute febrile illness and abdominal pain, prescribe empiric broad-spectrum antibiotics covering enteric gram-negative bacilli, gram-positive streptococci, and anaerobes—specifically, use a combination of ceftriaxone or cefotaxime PLUS metronidazole for mild-to-moderate community-acquired intra-abdominal infection, or escalate to piperacillin-tazobactam or a carbapenem (meropenem, imipenem-cilastatin, or ertapenem) for severe illness or healthcare-associated infection. 1

Risk Stratification Determines Antibiotic Choice

The selection of empiric antibiotics hinges on three critical factors:

• Infection origin: Community-acquired versus healthcare-associated 1
• Severity of illness: Mild-to-moderate versus severe physiologic disturbance, advanced age, or immunocompromised state 1
• Local resistance patterns: Particularly fluoroquinolone resistance in E. coli (now exceeding 10-20% in many regions) 1

Mild-to-Moderate Community-Acquired Infection

For patients with perforated appendicitis or other mild-to-moderate community-acquired abdominal infections:

First-Line Single-Agent Options:

• Ertapenem 1 g IV every 24 hours 1
• Moxifloxacin 400 mg IV every 24 hours (if local E. coli fluoroquinolone resistance <10-20%) 1
• Tigecycline 100 mg loading dose, then 50 mg IV every 12 hours 1
• Cefoxitin 2 g IV every 6 hours 1

First-Line Combination Regimens:

• Ceftriaxone 1-2 g IV every 12-24 hours PLUS metronidazole 500 mg IV every 8-12 hours 1
• Cefotaxime 1-2 g IV every 6-8 hours PLUS metronidazole 500 mg IV every 8-12 hours 1
• Levofloxacin 750 mg IV every 24 hours PLUS metronidazole 500 mg IV every 8-12 hours (only if local resistance data supports use) 1

Critical caveat: Avoid ampicillin-sulbactam due to high E. coli resistance rates, and avoid cefotetan and clindamycin due to increasing Bacteroides fragilis group resistance. 1

High-Severity or High-Risk Community-Acquired Infection

For patients with severe physiologic disturbance (septic shock, APACHE II score >15), advanced age, or immunocompromised state:

Preferred Single-Agent Options:

• Piperacillin-tazobactam 3.375 g IV every 6 hours (or 4.5 g every 6 hours for Pseudomonas coverage) 1
• Meropenem 1 g IV every 8 hours 1
• Imipenem-cilastatin 500 mg IV every 6 hours or 1 g every 8 hours 1
• Doripenem 500 mg IV every 8 hours 1

Alternative Combination Regimens:

• Cefepime 2 g IV every 8-12 hours PLUS metronidazole 500 mg IV every 8-12 hours 1
• Ceftazidime 2 g IV every 8 hours PLUS metronidazole 500 mg IV every 8-12 hours 1

Healthcare-Associated Intra-Abdominal Infection

For patients with recent hospitalization, recent antibiotic exposure, or nosocomial infection:

Empiric therapy must be driven by local antibiogram data and should include expanded gram-negative coverage. 1

Recommended Multidrug Regimens:

• Meropenem 1 g IV every 8 hours 1
• Imipenem-cilastatin 500 mg IV every 6 hours or 1 g every 8 hours 1
• Piperacillin-tazobactam 3.375-4.5 g IV every 6 hours 1
• Cefepime 2 g IV every 8 hours PLUS metronidazole 500 mg IV every 8-12 hours 1

Add vancomycin 15-20 mg/kg IV every 8-12 hours if MRSA is suspected based on local surveillance or patient risk factors. 1

Special Populations Requiring Enterococcal Coverage

Empiric enterococcal coverage is NOT routinely necessary for community-acquired infection 1, but consider adding ampicillin or vancomycin for:

• Immunocompromised patients with nosocomial post-operative peritonitis 2
• Patients with severe sepsis who previously received cephalosporins selecting for Enterococcus 2
• Patients with valvular heart disease or prosthetic intravascular material at high risk for endocarditis 2

Antifungal Therapy Considerations

Do NOT provide empiric antifungal coverage for community-acquired infection. 1

However, add fluconazole if Candida is grown from intra-abdominal cultures in patients with severe community-acquired or healthcare-associated infection. 1

Duration and De-escalation Strategy

• Initial broad-spectrum therapy should be narrowed based on culture results and clinical response at 48-72 hours 3, 4
• Prolonged broad-spectrum antibiotics increase risk of multidrug-resistant organism (MDRO) development 5, 4
• Median antibiotic duration for intra-abdominal infections is 8 days (IQR: 5-12 days), but this should be tailored to source control adequacy and clinical response 5

Common Pitfalls to Avoid

• Do not use aminoglycosides routinely in adults with community-acquired infection due to toxicity concerns, despite their inclusion in guidelines 1
• Avoid fluoroquinolones unless local E. coli susceptibility data confirms <10-20% resistance 1
• Do not prescribe extended-spectrum antibiotics (anti-pseudomonal agents) for mild-to-moderate community-acquired infection, as this increases toxicity risk and promotes resistance 1, 4
• Inadequate initial empiric therapy significantly increases mortality and hospital length of stay—err on the side of broader initial coverage in severely ill patients, then de-escalate 3